Sample · CapitalDart Deal
Solstice BioTherapeutics
A fictional deal screen showing matched investors, ranked contacts, and outreach status.
← Dashboard
Edit deal planContinue this dealArchive
Solstice BioTherapeutics
1 run · status active
Runs
5/24/2026, 5:17:35 PM · complete · target 100 · delivered 100
DownloadDeal Builder
Investors & Contacts
117 firms · 113 in directory
Status funnel · 117 contacts
Invested 1Prime 2Interested 3Awaiting response 3Not yet contacted 105Passed (had interest) 1Passed (no interest) 2Do not send 0
Search contacts…
StrategicActive 2yrAUMRating ↓| Contact | Firm | Location | AUM | Status | Tags | Ch. |
|---|---|---|---|---|---|---|
Sarah Chen Managing Director | Stonecreek Capital Partners Venture Capital · Rating 95 | Boston, MA, US | $1.2B | Prime | Top healthcare VC | ✉ in ↗ |
David Park Partner | Polaris Growth Equity Growth Equity · Rating 93 | San Francisco, CA, US | $3.8B | Prime | — | ✉ in ↗ |
Marcus Williams VP Corporate Dev | Belvedere Biosciences Fund Strategic · Rating 92 | New York, NY, US | $850M | Interested | — | ✉ in ↗ |
Lena Park Principal | Ridgeline Health Partners Venture Capital · Rating 90 | Cambridge, MA, US | $620M | Interested | — | ✉ in ↗ |
Thomas Reilly Managing Partner | Beacon Hill Ventures Venture Capital · Rating 88 | Austin, TX, US | $1.5B | Interested | — | ✉ in ↗ |
Sample data. Not a real deal.